Reduction of abdominal obesity through lifestyle measures can improve all components of the metabolic syndrome
and likely delay the development of both diabetes and atherosclerosis. Beyond lifestyle intervention, optimal
management of risk factors to evidence-based targets is essential. High awareness of health problems caused due to
change in lifestyle and optimal management of risk factors can improve the metabolic syndrome and likely reduce the
development of both diabetes and atherosclerosis and hence reducing the demand for the atherectomy devices. The
major companies of the Atherectomy Devices Market include Bayer AG, Cardiovascular systems, St. Jude medica,
Boston scientific corporation, Abbott laboratories, C.R Bard Inc., Volcano Corporation. The competition in this
Atherectomy Devices Market usually depends on the technology used in manufacturing of the devices and also the
pricing strategies. Medtronic’s is leading competitor in peripheral atherectomy devices. Medtronic acquired Covedian
in 2015 and is expected to remain in the leading position however it will face increasing competition from
cardiovascular systems Inc.
See More Reports of This Category by Million Insights @
https://www.millioninsights.com/industry/medical-devices
Market Segment:
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million
USD), market share and growth rate of Atherectomy Devices in these regions, from 2013 to 2025 (forecast), covering
• North America
• Europe
• China
• Japan
• Southeast Asia
• India
Global Atherectomy Devices market competition by top manufacturers, with production, price, revenue (value) and
market share for each manufacturer; the top players including
• Boston Scientific Corp.
• Cardiovascular Systems Inc.
• Medtronic Plc